Abstract: The present invention relates to a solid, effervescent, rapidly dissolving dosage form for oral administration, of (a) cetirizine or a pharmaceutically acceptable salt thereof, (b) an effervescent base comprising (i) at least one of (1) an organic edible acid and (2) a salt thereof, (ii) at least one of an alkali metal and an alkaline earth metal carbonate and bicarbonate, and (c) optionally a pharmaceutically acceptable auxiliary ingredient.

Abstract: The invention relates to an effervescent, rapidly disintegrating oral dosage form of (a) an alkali-sensitive active ingredient, (b) an effervescent base comprising at least one of (i) at least one alkaline earth metal carbonate, (ii) an organic edible acid, and (iii) an alkali metal salt of citric acid, and optionally (c) a pharmaceutically acceptable auxiliary ingredient, and to a process for preparing the dosage form.

Abstract: A process for producing a granulated material from a powder mixture containing at least two components, one of which is in crystal or crystalline form and at least one contains water of crystallization and/or is reactive, granulation is carried out in an inclined drum. Powder is fed in at one end and granulate removed at the other, after being transported inside the drum for a desired period while the drum is rocked in a way which largely eliminates shear forces. A quantity of liquid at least approximately equal to the quantity of water of crystallization present and sufficient for the formation of a superficially active solution adhesive is released inside the drum, where appropriate by partial reaction of the reactive component(s), after which the powder mixture components are granulated by surface adhesion.

Abstract: Pharmaceutical preparation in tablet form for supplying fluoride ions for the treatment and prevention of losses of bone substance, including osteoporosis and alveolar bond damage, with a content of sodium fluorophosphate and substances for regulating the release of sodium fluorophosphate, the substances for the regulation of the sodium fluorophosphate release comprising a dual retardant system which consists of a retardant matrix in the tablet core and a retardant coating.